Document is current
Any future updates will be listed below
-
Authors
Marasco, Giovanni https://orcid.org/0000-0001-7167-8773
Barbara, Giovanni
Bellini, Massimo
Portincasa, Piero
Stanghellini, Vincenzo
Annibale, Bruno
Benedetti, Antonio
Cammarota, Giovanni
Fries, Walter
Usai Satta, Paolo
Corazziari, Enrico Stefano
-
Funding
Funding for this research was provided by:
Messaggi International Publisher & Events srl, Milan Italy
Alma Mater Studiorum - Università di Bologna
- License Information
-
More Information
Article History
Received: 17 April 2025
Accepted: 8 July 2025
First Online: 12 September 2025
Declarations
:
: Annibale B: Alfasigma, Aboca. Barbara G: Aboca, Ab Biotics, Agave, Alfasigma, Ag Pharma, Bayer, Biocodex, Boheringer, Bromatech, Cadigroup, Danone, Diadema, Falk Pharma, Ge Healthcare, Giuliani, Mayoly, Malesci, Monteresearch, Sanofi, Sofar, Yakult. Bellini M: Alfasigma, Diadema, Agave, Ferring, Ag Pharma, Bromatech, Sila, Depofarma. Cammarota G: Aurora Biopharma, Delta Pharma. Corazziari ES: Aboca spa, Sofar spa, Alfasigma spa, GE Healthcare. Fries W: Abbvie, Pfizer, Janssen, Galapagos. Marasco G: Aboca, AgPharma, AlfaSigma, Bayer, Bromatech, CINECA, Clorofilla, Coreresearch, Echosens, EG Pharma, Eli Lilly, Ferring, Giuliani, Malesci, Mayoly Spindler, Menarini, Monteresearch, Named, Noos, Galenika, Recordati, Schwabe Pharma, Unifarco. Portincasa P: Aboca, Allergosan, Omega Pharma. Stanghellini V: Alfasigma, Bayer, Bromatech, Ge Healthcare. Usai Satta P: Alfasigma. Benedetti A declares no conflict of interest.
: The present survey investigated knowledge about the management of BAD in a group of Italian physicians without any involvement of patients. All physicians provided electronic informed consent before participation, and data were collected anonymously. The study was deemed exempt from ethics approval.
